Akeso, Inc. (HKG:9926)
Hong Kong
· Delayed Price · Currency is HKD 92.50
-2.35 (-2.48%)
Jun 27, 2025, 4:08 PM HKT
Akeso Revenue
In the year 2024, Akeso had annual revenue of 2.12B CNY, down -53.08%. Akeso had revenue of 1.10B in the half year ending December 31, 2024, with 62.96% growth.
Revenue
2.12B CNY
Revenue Growth
-53.08%
P/S Ratio
36.73
Revenue / Employee
699.82K CNY
Employees
3,035
Market Cap
83.03B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| Innovent Biologics | 10.03B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Akeso News
- 26 days ago - Chinese biotech firm Akeso sinks after US partner’s cancer-drug setback - South China Morning Post
- 2 months ago - Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
- 2 months ago - China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug - South China Morning Post
- 2 months ago - What's Going On With Summit Therapeutics Stock On Friday? - Benzinga
- 2 months ago - Why Is Summit Therapeutics Stock Soaring On Wednesday? - Benzinga
- 2 months ago - Akeso (9926) Poised for Growth Despite Current Undervaluation - GuruFocus
- 2 months ago - Bullish On Akeso's Ivonescimab, But Valuation And Geopolitical Risks Remain - Seeking Alpha
- 2 months ago - Why This Chinese Biotech Could Be Pharma's DeepSeek - Benzinga